(Q35708836)

9 August 2017

1 reference

title

Identifying epitopes of HIV-1 that induce protective antibodies (English)

1 reference

9 August 2017

1 reference

0 references

Susan Zolla-Pazner

1 reference

9 August 2017

publication date

1 March 2004

1 reference

Nature Reviews Immunology

9 August 2017

published in

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

199-210

1 reference

Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum

9 August 2017

cites work

1 reference

Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications

31 March 2020

1 reference

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

31 March 2020

1 reference

Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies

31 March 2020

1 reference

Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope

31 March 2020

1 reference

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

31 March 2020

1 reference

Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody

31 March 2020

1 reference

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

31 March 2020

1 reference

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

31 March 2020

1 reference

Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates

31 March 2020

1 reference

Human immunodeficiency virus (HIV) type 1 antibodies in perinatal HIV-1 infection: association with human HIV-1 transmission, infection, and disease progression. For the Women and Infants Transmission Study

31 March 2020

1 reference

Antibodies, viruses and vaccines

31 March 2020

1 reference

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

31 March 2020

1 reference

Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization

31 March 2020

1 reference

HIV entry and its inhibition

31 March 2020

1 reference

Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41

31 March 2020

1 reference

Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates

31 March 2020

1 reference

Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions

31 March 2020

1 reference

Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization

31 March 2020

1 reference

AIDS vaccines: back to 'plan A'.

31 March 2020

1 reference

Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins

31 March 2020

1 reference

Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding

31 March 2020

1 reference

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

31 March 2020

1 reference

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

31 March 2020

1 reference

Epitope exposure on functional, oligomeric HIV-1 gp41 molecules

31 March 2020

1 reference

Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

31 March 2020

1 reference

Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites

31 March 2020

1 reference

Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12

31 March 2020

1 reference

Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein

31 March 2020

1 reference

Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.

31 March 2020

1 reference

A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates

31 March 2020

1 reference

Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies

31 March 2020

1 reference

Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120.

31 March 2020

1 reference

A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates

31 March 2020

1 reference

Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro

31 March 2020

1 reference

Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates

31 March 2020

1 reference

Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120.

31 March 2020

1 reference

Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120

31 March 2020

1 reference

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

31 March 2020

1 reference

Determinants of HIV-1 coreceptor function on CC chemokine receptor 3. Importance of both extracellular and transmembrane/cytoplasmic regions

31 March 2020

1 reference

Identification of a major co-receptor for primary isolates of HIV-1

31 March 2020

1 reference

Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies

31 March 2020

1 reference

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes

31 March 2020

1 reference

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

31 March 2020

1 reference

Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor

31 March 2020

1 reference

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

31 March 2020

1 reference

Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein

31 March 2020

1 reference

HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope

31 March 2020

1 reference

Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein

31 March 2020

1 reference

New hope for an AIDS vaccine

31 March 2020

1 reference

Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci

31 March 2020

1 reference

Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120.

31 March 2020

1 reference

The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts

31 March 2020

1 reference

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

31 March 2020

1 reference

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

31 March 2020

1 reference

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

31 March 2020

1 reference

Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees

31 March 2020

1 reference

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

31 March 2020

1 reference

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

31 March 2020

1 reference

V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.

31 March 2020

1 reference

Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies

31 March 2020

1 reference

Molecular characterization of five human anti-human immunodeficiency virus type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response

31 March 2020

1 reference

Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus

31 March 2020

1 reference

The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor

31 March 2020

1 reference

Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization

31 March 2020

1 reference

Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity

31 March 2020

1 reference

Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.

31 March 2020

1 reference

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.

31 March 2020

1 reference

Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells

31 March 2020

1 reference

Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype

31 March 2020

1 reference

Importance of basic residues and quaternary structure in the function of MIP-1 beta: CCR5 binding and cell surface sugar interactions

31 March 2020

1 reference

A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope

31 March 2020

1 reference

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

31 March 2020

1 reference

Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design

31 March 2020

1 reference

Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains

31 March 2020

1 reference

The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma.

31 March 2020

1 reference

Identification of HIV Vaccine Candidate Peptides by Screening Random Phage Epitope Libraries

31 March 2020

1 reference

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

31 March 2020

1 reference

Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility

31 March 2020

1 reference

NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding

31 March 2020

1 reference

Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide

31 March 2020

1 reference

Characterization of murine coronavirus neutralization epitopes with phage-displayed peptides

31 March 2020

1 reference

Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2.

31 March 2020

1 reference

Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay

31 March 2020

1 reference

Diversity considerations in HIV-1 vaccine selection

31 March 2020

1 reference

A general model for the transmembrane proteins of HIV and other retroviruses

31 March 2020

1 reference

HIV. Escape artist par excellence

31 March 2020

1 reference

Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain

31 March 2020

1 reference

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

31 March 2020

1 reference

Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts

31 March 2020

1 reference

12 December 2020

Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assay

1 reference

12 December 2020

Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization

1 reference

12 December 2020

Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies

1 reference

12 December 2020

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

2 references

12 December 2020

7 January 2021

inferred from DOI database lookup

A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1

1 reference

12 December 2020

Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells

1 reference

12 December 2020

Neutralization of animal viruses

1 reference

12 December 2020

The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

1 reference

12 December 2020

Multivariate analysis of human immunodeficiency virus type 1 neutralization data

1 reference

12 December 2020

Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine

1 reference

12 December 2020

Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies

1 reference

12 December 2020

Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization

1 reference

12 December 2020

Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1.

1 reference

12 December 2020

Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies

1 reference

12 December 2020

Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1

1 reference

12 December 2020

CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization

1 reference

12 December 2020

Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV

1 reference

12 December 2020

A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.

1 reference

12 December 2020

Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

1 reference

12 December 2020

Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies

1 reference

12 December 2020

Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.

1 reference

12 December 2020

Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

1 reference

12 December 2020

Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding

1 reference

12 December 2020

Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.

1 reference

12 December 2020

Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody

1 reference

12 December 2020

An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

1 reference

12 December 2020

Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.

1 reference

12 December 2020

Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120

1 reference

12 December 2020

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

12 December 2020

Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D

1 reference

12 December 2020

Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120

1 reference

12 December 2020

Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera.

1 reference

12 December 2020

Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1

1 reference

12 December 2020

A mimotope from a solid-phase peptide library induces a measles virus-neutralizing and protective antibody response

1 reference

12 December 2020

Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein

1 reference

12 December 2020

Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization

1 reference

12 December 2020

Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding

1 reference

12 December 2020

Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody

1 reference

12 December 2020

Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide

1 reference

12 December 2020

Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization

1 reference

12 December 2020

Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRI1307

1 reference

9 August 2017

1 reference